Commack: 
Regeneron
New Treatment for Diabetic Macular Edema
Enrollment is Closed
About this Study
A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edema.
This study is using a higher concentration of Eylea with the hope that patients will need injections much less frequently, hopefully, every 3-4 months and still maintain visual improvements.
Genentech Lucerne Study
Enrollment is Closed
This is a new drug called faricimab that may allow us to dose less frequently for wet AMD
Opthea
New Treatment for Neovascular Age-Related Macular Degeneration
Enrollment is Open
About this Study
This is a phase 3 study looking at adding a new molecule in addition to Lucentis or Eylea. It is hoped that patients will have better results and less frequent treatment.
New Treatment for Diabetic Eye Disease
Enrollment is Open
About this Study
This is a phase 2 study looking at an oral treatment (pill) to treat moderately severe to severe nonproliferative diabetes retinopathy and mild proliferation diabetic retinopathy.
Genentech Yosemite Study
New Treatment for Diabetic Macular Edema
Study is now closed
About this Study
This is a phase 3 study looking at a new drug RO6867461. It has the potential to improve vision with fewer eye injections.
GlaxoSmithKline Study
New treatment for diabetic macular edema
Enrollment is open
About this Study
Phase 1 study looking at an oral medication (pill) to treat diabetic macular edema.